Full-Time
Registered Nurse – Critical Care Float Pool
Nights
Memorial Hermann
10,001+ employees
Integrated health system delivering patient-centered care
No salary listed
United States
In Person
Bachelor's
 Medical, Clinical & Veterinary (1) |
|---|
Get referred to Memorial Hermann
See people who can refer or advise you
- Graduation from an accredited School of Professional Nursing.
- A current State of Texas license or temporary/compact license to practice professional nursing is required.
- Certification in Basic Life Support is required.
- Additional certifications may be required based on discipline or nursing unit requirements.
- Effective oral and written communication skills are required.
- RN I corresponds to less than 1 year of experience; RN II corresponds to 1–3 years; RN III corresponds to 3–10 years; and RN IV corresponds to 10 or more years.
- Collaborate with physicians and the healthcare team in delivering patient care using the nursing process.
- Provide professional nursing care, including conducting nursing assessments, assisting with examinations and treatment, educating patients, and maintaining medical records.
- Deliver safe and appropriate care according to the nursing skills inventory and the age and needs of the patient population served.
- Coordinate nursing-care planning with an interdisciplinary team and make appropriate clinical decisions in patient care delivery.
- Collaborate with, direct, and delegate to the healthcare team to achieve positive outcomes based on data, research, evidence, and professional standards of care.
- Coordinate treatment plans and develop and implement discharge or transfer plans.
- Participate in systemic, interdisciplinary, and ongoing evaluation of programs, process improvement, and client-centered outcomes.
- Address each patient's diverse needs across the continuum of care while ensuring service standards and optimizing the patient experience.
- Adhere to regulatory requirements and Texas Board of Nursing standards.
- Ensure safe care for patients, staff, and visitors while following Memorial Hermann policies, procedures, and standards and stewarding time, supplies, productivity, and service quality.
- Meet mandatory and continuing-education and skills-competency requirements to support professional growth and development.
- Support department-based goals that contribute to organizational success.
- Perform other duties as assigned.
- A Bachelor of Nursing degree is preferred.
Memorial Hermann Health System is a nonprofit, community-owned health system serving the Greater Houston area with more than 260 care delivery sites. It delivers safe, high-quality, patient-centered care through an integrated network that combines clinical expertise with advanced technology. The system differentiates itself through its community ownership, value-driven culture, and broad network of hospitals, clinics, and specialty services. Its goal is to improve regional health outcomes by providing comprehensive, accessible care and leveraging innovation to personalize treatment.
Company Size
10,001+
Company Stage
Grant
Total Funding
$5M
Headquarters
Houston, Texas
Founded
1907
Get referred to Memorial Hermann
See people who can refer or advise you
Simplify's Take
What believers are saying
- Texas awarded Memorial Hermann $750,000 on June 10, 2026 to expand its mobile stroke unit.
- Cadence partnership, announced April 30, 2026, deepens chronic-care monitoring for hypertension, CHF, and diabetes.
- HEAL High School opens a talent pipeline by 2028, supported by Bloomberg’s $31 million gift.
What critics are saying
- BCBSTX pushed Memorial Hermann out-of-network April 1, 2026, pressuring revenue and patient retention.
- February 6, 2026 voluntary buyouts signal margin strain and management’s two-and-a-half-year restructuring plan.
- A misstep in Houston’s crowded market could cede insured patients to Methodist, HCA, and Baylor.
What makes Memorial Hermann unique
- Memorial Hermann launched America’s first mobile stroke unit in 2014, setting Houston’s stroke standard.
- HEAL High School’s 6,500-square-foot simulated hospital embeds Memorial Hermann clinicians into workforce training.
- Memorial Hermann and Helix Genomic Advantage bring precision medicine to employee populations, starting June 16, 2026.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Professional Development Budget
Wellness Program
Mental Health Support
Growth & Insights and Company News
6 month growth
↑ 14%1 year growth
↑ 14%2 year growth
↑ 14%Helix secures AstraZeneca partnership to power drug discovery with US genomic data. July 8, 2026 AstraZeneca has signed a multi-year agreement with San Mateo-based Helix to access its GenoSphere clinico-genomic cohort platform for drug discovery and development, adding a major US commercial data source to its existing population genomics infrastructure. The deal gives AstraZeneca (Nasdaq: AZN) access to Helix's continuously growing, deeply phenotyped cohorts spanning cardiometabolic, respiratory, and autoimmune disease areas. The agreement is AstraZeneca's latest move in a systematic multi-source genomics strategy and arrives as Helix establishes itself as a recurring platform partner to top-tier pharma. Financial terms were not disclosed. GenoSphere cohorts combine Exome+ genomic sequencing with longitudinal electronic health record data averaging 13 years of follow-up per patient, drawn from the Helix Research Network - described by the company as the largest precision health network in North America. The datasets are de-identified and fully consented, with the option to launch targeted follow-on studies. The platform is designed to support target identification, disease biology research, and patient stratification across the drug development lifecycle, functioning as a discovery infrastructure layer rather than a single-indication tool. Helix recently launched its Genomic Advantage program with Nebraska Medicine and Memorial Hermann Health System, adding new health system partners that feed the underlying research network. For AstraZeneca, the Helix deal adds a commercially managed, US-based, exome-sequenced cohort to a genomics portfolio that already includes co-funded access to the UK Biobank whole-genome sequencing dataset and membership in the Alliance for Genomic Discovery - a consortium that includes AbbVie, Amgen, GSK, Merck, and Novo Nordisk, among others. AstraZeneca's Centre for Genomics Research has publicly stated a goal of analyzing 2 million genomes by 2026. The Helix agreement adds a North American commercial data layer to AstraZeneca's existing European biobank partnerships. Helix previously signed a multi-year collaboration with GSK, announced in January 2026 using an identical structural template, with AstraZeneca now the third major pharma to sign onto the same GenoSphere platform following Helix's March 2026 agreement with Alnylam Pharmaceuticals. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/
Cadence, the clinical AI company managing chronic care for older adults, announced a $100 million Series C, amid adoption of its AI-powered care model across...
Nebraska Medicine and Memorial Hermann Health System have launched Helix Genomic Advantage, integrating clinical-grade genomic insights into care delivery for their workforces. The programme follows a similar launch with St. Luke's University Health Network. Both health systems are Helix Research Network partners operating large-scale community genomics studies. The Genomic Advantage model aims to implement precision medicine for targeted populations whilst reducing costs, addressing the high expense that has historically prevented scaling diagnostic genomics. "The high cost of diagnostic genomics has served as a significant barrier, preventing health systems from scaling these insights for patient populations," said James Lu, Helix CEO and co-founder. The programme aligns incentives to drive expanded access and total cost of care reduction across risk-based populations.
Memorial Hermann Is Leaving the Houston Market. Here's What Every Business Owner and HR Manager Needs to Know
Two new health systems launch Helix Genomic Advantage(TM) to improve care and lower cost across their risk-based populations. June 16, 2026 SAN MATEO, Calif., June 16, 2026 - Two more of the country's leading health systems are making genomic medicine a standard of care for their own employees. Nebraska Medicine and Memorial Hermann Health System today announced the launch of Helix Genomic Advantage(TM), integrating clinical-grade genomic insights directly into how they deliver care for their workforce. This comes on the heels of the launch of Helix Genomic Advantage with St. Luke's University Health Network. The Helix Genomic Advantage model enables organizations to implement precision medicine for targeted populations that delivers both expanded clinical access and cost-reduction. "The integration of genomic data into routine clinical practice is the next frontier of medical innovation," noted Kyle Skiermont, PharmD, Nebraska Medicine Chief Operating Officer. "The initiative underscores the essential role that academic health systems play in translating complex genetic discovery into actionable, everyday clinical workflows." Nebraska Medicine and Memorial Hermann Health System are active Helix Research Network(R) partners that have built research programs needed to progress genomics research. Each runs a large-scale community genomics study, the Genetic Insights Project and GenoME(R), respectively, providing free genetic screening to participants. Both have added Helix Genomic Advantage as a new program for targeted populations. "We have always prioritized the health and wellness of our team members, recognizing that they are the heart of everything we do," said Dr. James McCarthy, Executive Vice President and Chief Physician Executive, Memorial Hermann Health System. "Investing in our employees' future in this way is not merely a benefit; it is a core expression of our culture and our commitment to leading the future of healthcare from within our own organization." "For years, the high cost of diagnostic genomics has served as a significant barrier, preventing health systems from scaling these insights for patient populations," said James Lu, M.D., Ph.D., CEO and co-founder of Helix. "Helix Genomic Advantage aligns Helix's incentives with our partners to drive both expanded access and total cost of care reduction. Together, we can better integrate genomics across the care continuum." Helix Genomic Advantage extends Helix's proven track record of helping health systems implement large-scale population genomics by providing a structured, cost-efficient framework specifically designed for at-risk populations. This evolution enables organizations to seamlessly integrate sustainable genomic insights into their enterprise strategies. About Helix: Helix is the leading enterprise genomics platform. The company transforms health systems and enables life science organizations to leverage the power of genomics across their enterprise, creating strategic value and fueling future growth. The Helix Research Network(R)- the largest precision health network in the world - accelerates genomic discoveries and translates them into real-world clinical impact. Learn more at www.helix.com.